加载中
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
前收盘价
US$1.47
+US$0.02 · +1.38%
盘前
US$1.48
+US$0.01 · +0.68%
10月12日 4:00 ET
盘中时间采用ET。市场数据可能有所延迟。
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
日内区间
当前US$1.47
52周区间
当前US$1.47
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
17
估值过高
情绪
53
多空交织
风险
66
高风险
动量
40
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
日内区间
当前US$1.47
52周区间
当前US$1.47
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7.21万 USD | 7.21万 USD | 7.21万 USD | 7.21万 USD | 7.13万 USD |
| 销货成本 | 88.61万 USD | 5838 USD | 5838 USD | 5838 USD | 5004 USD |
| 毛利 | −81.4万 USD | 6.63万 USD | 6.63万 USD | 6.63万 USD | 6.63万 USD |
| 研究与开发 | 216.08万 USD | 236.82万 USD | 84.51万 USD | 128.64万 USD | 69.39万 USD |
| 销售、一般及管理费用 | 214.76万 USD | 240.38万 USD | 307.68万 USD | 242.75万 USD | 226.52万 USD |
| 营业费用 | 346.67万 USD | 477.2万 USD | 392.19万 USD | 369.39万 USD | 281.06万 USD |
| 利息收入 | 19.39万 USD | 33.32万 USD | 39.85万 USD | 7.26万 USD | 1210 USD |
| 利息支出 | 3.73万 USD | 5084 USD | 4869 USD | 2199 USD | 3036 USD |
| 折旧和摊销 | 1.14万 USD | 6185 USD | — | — | — |
| 营业利润 | −428.07万 USD | −470.57万 USD | −385.56万 USD | −362.77万 USD | −274.43万 USD |
| 净利润 | −422.77万 USD | −439.29万 USD | −370.07万 USD | −390.86万 USD | 390.37万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年6月3日 | 1:15 | — | — |
股票拆分 | 2022年9月15日 | 1:50 | — | — |
已生效 2026年6月3日
1:15
已生效 2022年9月15日
1:50
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
